Avid Bioservices Inc (CDMO)

[Protector]

biopharm, for starters we'll get a CT ORDER on EDGAR. It will probably contain some NON-DISCLOSED terms about the agreement.

Second, a world-class team with such a reputation does NOT take on any research. They are aware that all offers that come their way are aimed to connect their name and reputation with the research.

Furthermore they can PICK whatever they want because they'll have the choice.

From PPHM's perspective this is a GREAT MOVE. Moulding it in a Research Collaboration formula where PPHM participates gives them insight on what is going on while keeping the cost low. Yet MSK is a more NEUTRAL party. So BP's can now sub-sponsor them to take THEIR drug in combination research first.

Afterwards PPHM can close the licensing and make the collaboration/partnership deals. That is good in that there will be MUCH FASTER ... MUCH MORE combinations tested.

And with Dr. Wolchok writings that you sited:

“I believe it is finally time to start thinking realistically about long-term remissions, even cures, because we can now combine standard therapies that target the tumor with immunotherapies that boost a patient’s own defenses,” Dr. Wolchok writes in “New Drugs Free the Immune System to Fight Cancer.” (Subscription is required for access to the full article.)

And his statement in PPHM's PR:

"The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr. Wolchok.

I think that Dr. Merghoub, in Wolchok's Lab, will be kept on a short leash to research exactly those combinations that aim at making the dream in the first quote reality. Furthermore Dr. Merghoub will be very dedicatively involved in this. Its not every day you may work on potential cures of cancer. It put you on the map.

This are no longer Hansel and Gretel saying Bavituximab is a generic target/upstream or global target (whatever it was called in the past), this is the US #1 Research Center saying it by it's TOP ONCOLOGY RESEARCHER.